Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate

Obstetrics and Gynecology

Volumn 108, Issue 4, 2006, Pages 969-978

  Simoncini, Tommaso ^a   Caruso, Antonella ^a   Garibaldi, Silvia ^a   Fu, Xiao Dong ^a   Giretti, Maria Silvia ^a   Baldacci, Chiara ^a   Scorticati, Camila ^a   Fornari, Letizia ^a   Mannella, Paolo ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOMEGESTROL ACETATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE;

ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELLS, CULTURED; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; ESTRADIOL; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL; MIFEPRISTONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORPREGNADIENES; PROGESTERONE; PROGESTERONE CONGENERS; SIGNAL TRANSDUCTION;

EID: 33749324438     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000233184.64531.84     Document Type: Article

References (39)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
2. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7.
3. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
4. Genazzani AR, Gambacciani M, Simoncini T. Estrogens and women's health: a scary or a fairy tale? Gynecol Endocrinol 2004;18:175-8.
5. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative [published erratum appears in Arch Intern Med. 2006;166:759]. Arch Intern Med 2006;166:357-65.
6. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxy-progesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997;3:324-7.
7. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 1998;64:187-91.
8. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
9. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, et al. Natural progesterone, but not medroxy-progesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154-9.
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
12. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001;21:243-8.
13. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003;148:281-92.
14. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-56.
15. Nilsen J, Chen S, Brinton RD. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Res 2002;930:216-34.
16. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 2003;100:10506-11.
17. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.
18. Hague S, MacKenzie IZ, Bicknell R, Rees MC. In-vivo angiogenesis and progestogens. Hum Reprod 2002;17:786-93.
19. Wagner JD, Thomas MJ, Williams JK, Zhang L, Greaves KA, Cefalu WT. Insulin sensitivity and cardiovascular risk factors in ovariectomized monkeys with estradiol alone or combined with nomegestrol acetate. J Clin Endocrinol Metab 1998;83:896-901.
20. Simoncini T, Apa R, Reis FM, Miceli F, Stomati M, Driul L, et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 1999;84:2802-6.
21. Knowles RG, Salter M. Measurement of NOS activity by conversion of radiolabeled arginine to citrulline using ion-exchange separation. In: Titheradge MA, editor. Nitric oxide protocols. Totowa (NJ): Humana Press; 1998. p. 67-73.
22. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966-9.
23. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-41.
24. Simoncini T, Rabkin E, Liao JK. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:198-203.
25. Simoncini T, Maffei S, Basta G, Barsacchi G, Genazzani AR, Liao JK, et al. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res 2000;87:19-25.
26. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-83.
27. Li X, O'Malley BW. Unfolding the action of progesterone receptors. J Biol Chem 2003;278:39261-4.
28. Zhang R, Min W, Sessa WC. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem 1995;270:15320-6.
29. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998;31:582-8.
30. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002;23:665-86.
31. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8.
32. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-9.
33. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998;18:1164-71.
34. Paris JM, Williams KJ, Hermsmeyer KR, Delansorne R. Nomegestrol acetate and vascular reactivity: nonhuman primate experiments. Steroids 2000;65:621-7.
35. Williams JK, Delansorne R, Paris J. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys. J Steroid Biochem Mol Biol 1998;65:219-24.
36. Sorensen MB, Collins P, Ong PJL, Webb CM, Hayward CS, Asbury EA, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646-51.
37. Williams JK, Cline JM, Honore EK, Delansorne R, Paris J. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis). Am J Obstet Gynecol 1998;179:1288-94.
38. Dorangeon P, Thomas JL, Choisy H, Lumbroso M, Hazard MC. Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab 1993;19:441-5.
39. Conard J, Basdevant A, Thomas JL, Ochsenbein E, Denis C, Guyene TT, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995;64:957-62.